Why the Michael J. Fox Foundation Advocates for Cannabis Research

The Michael J. Fox Foundation for Parkinson’s Research (MJFF), which was established by and is named after the actor who has the disease, continues to advocate for cannabis research. As reported by Marijuana Moment, the group is currently pushing Congress to pass three bills relating to cannabis research and medical marijuana; the Medical Cannabis Research Act, VA Medicinal Cannabis Research Act and Expanding Cannabis Research and Information Act.  “Our role on the public policy team is to work with Congress and the administration to ensure there is access and funding for research and care initiatives that can benefit people living with Parkinson’s and, right now, that includes access to medical cannabis for research,” Ted Thompson, the foundation’s senior vice president of public policy, said. According to the MJFF site, the public policy team is currently tracking these bills and aims to inform members of Congress and their staff as to why the bills matter to the Parkinson’s community.

Spotlight

StatRad

Built from the ground up by physicians for physicians, StatRad has been passionately dedicated to providing the very best in patient care while constantly improving our service to our partners through the latest advances in technology. Established in 1996, we partnered with local radiology groups to provide coverage after normal business hours. In 2001, we introduced an innovative teleradiology platform to accelerate transmissions, streamline workflows, increase productivity and improve communication among physicians. Today, we’re maintaining our pioneering spirit by introducing new innovations to the market on a regular basis and providing the technology, expertise and service to help our clients deliver excellent care.

OTHER ARTICLES
Research

Immunology: A New Frontier in Medical Science

Article | July 11, 2022

Introduction Recent developments in the bioengineering of monoclonal antibodies (mAbs) have revolutionized the treatment of numerous rheumatic and immunological disorders. Currently, several immunological disorders are successfully being targeted and treated using innovative medical techniques such as immunotherapy. Leading companies are increasingly investing in research activities to expand the usage and application of immunology for the treatment of various infectious diseases, including multiple sclerosis, inflammatory bowel disorders, lupus, and psoriasis, leading companies are increasingly investing in research activities. Today, the efforts of researchers in immunology, with a long history of study and research, have borne fruit, as bioengineered mAbs are now being employed in clinical practices. Accelerating Investments: Paving the Way for Immunology The increasing prevalence of infectious diseases, cancer, and immune-mediated inflammatory disorders (IMIDs) is raising the need for more precise classification and an in-depth understanding of the pathology underlying these ailments. Numerous leaders in the biotechnology domain are thus focusing on undertaking numerous strategies, such as new facility launches and collaborations, to address the need by finding deeper inroads into immunology and its use in disease treatments. For instance, in 2022, the University of Texas MD Anderson Cancer Center announced the launch of a visionary research and innovation hub, the James P. Allison Institute, to find new roads in immunotherapy, develop new treatments, and foster groundbreaking science. These developments will result in better diagnosis through the use of selective biomarkers, and early detection of fatal diseases and their treatment, which will prevent complications from happening. Also, the identification of high-risk populations through a deeper understanding of genetic and environmental factors can assist in the prevention of disease through immunotherapy. The Way Forward Immunology has led to the development of biotechnology, making it possible to develop novel drugs and vaccines, as well as diagnostic tests, that can be used to prevent, diagnose, and treat a wide range of autoimmune, infectious, and cancerous diseases. With the rapid advancement in technology and the integration of artificial intelligence, immunology is finding its way into an array of domains and industries, encompassing several research areas including medicine, pharmaceuticals, agriculture, and space. Today, not only researchers but also leading biotech and pharmaceutical companies have recognized that conventional therapies with pharmaceutical and chemical products are being replaced by products derived from immunology. This is because they work well for health problems, are environmentally friendly, and are also emerging as a wealth-generating business in the medical field.

Read More
MedTech

AI and Biotechnology: The Future of Healthcare Industry

Article | July 16, 2022

Artificial intelligence has grasped the foundation in biotech. It can have the most innovative impact on biotechnology. AI has already established its presence in our day-to-day life. AI has made the existence of self-driving cars possible. Likewise, the benefits and quality that it can contribute to biotech can also be felt. With AI, bio technicians will be able to enhance virtual screening, overlook preliminary datasets from clinics, and decipher an enormous amount of information. It can also help in improving the medication process by gathering and analyzing every bit of information. The Significance of AI in Biotechnology In the past few years, the application of artificial intelligence in the biotechnology industry has shifted from being sci-fi to sci-fact. A vast number of biotech companies like Deep Genomics are adopting AI for making data-driven decisions and use analytics tools to work efficiently. Unlike the AI robots in sci-fi that are ready to take over the world. AI designed for biotech has been designed to solve certain problems or complete a bunch of tasks by using automated algorithms. The aim of AI technology for biotech is to collect insights along with hidden patterns from large amounts of data. All the different industries of biotech including agriculture, animal, medical, industrial, and bioinformatics are gradually being affected by artificial intelligence. Moreover, the biotech industry is realizing that AI enables them some of the important strength to their business, including: Expanding accessibility Cost-effectiveness Critical predictions Efficient decision-making Research centers like PwC have also estimated output of $15.7 trillion by 2030 solely with AI contribution in industries. A survey revealed that about 44% of life science experts are using AI for R&D activities, as well. Use of AI in Biotechnology Altering Biomedical and Clinical Data So far the most developed use of AI is its ability to read voluminous data records and interpret them. It can prove to be a life-save for bio technicians who would have to examine that much data from research publications by themselves for the validation of their hypothesis. With the help of AI, clinical studies of patients will also become easier as all the examination reports and prescriptions will be stored in one place for cross-reference. Furthermore, it will also help in blending and fetching data into usable formats for analysis. Test Result Prediction Through trial and error, AI along with machine learning can help in predicting the response of the patient to certain drugs to provide more effective outcomes. Drug Design & Discovery AI plays a vital role whether it’s designing a new molecule or identifying new biological targets. It helps in identifying and validating drugs. It reduces the cost and time spent on the entire drug trial process and reaches the market. Personalized Medications for Rare Diseases With the combination of body scan results, patients’ body and analytics, AI can also help in detecting dangerous diseases at an early stage. Improving Process of Manufacturing To improve the process of manufacturing in biotechnology, AI offers a wide range of opportunities. It controls quality, reduces wastage, improves useability, and minimizes the designing time. Moving Towards AI-Enhanced Biotech Future Ever since the concept of artificial intelligence has arrived, being curious by nature, humans have started working towards achieving this goal. It has been growing at a fast pace while showing unbelievable growth and achievements at times. In comparison to the traditional methods used in the biotechnology industry, AI-based methods seem more reliable and accurate. In the upcoming years, it will show its success by improving the quality of health people have. You can also develop your AI-based application or know more about it by taking IT consultations.

Read More
MedTech

Next-Gen Gene Therapy to Counter Complex Diseases

Article | July 11, 2022

Gene therapy has historically been used to treat disorders with in-depth knowledge caused by a single genetic mutation. Thanks to the introduction of new generation technologies, the potential of gene therapy is expanding tAo treat diseases that were previously untreatable. Evolution of Gene Therapy One of the major success stories of the twenty-first century has been gene therapy. However, it has not been the same in the past. The field's journey to this point has been long and mostly difficult, with both tragedy and triumph along the way. Initially, genetic disorders were thought to be untreatable and permanently carved into the genomes of individuals unfortunate enough to be born with them. But due to the constant technological advancement and research activities, gene therapy now has the potential to treat various genetic mutation-causing diseases with its ability to insert a new copy and replace faulty genes. Gene Therapy is Finding New Roads in the Medical Sector Gene therapy can help researchers treat a variety of conditions that fall under the general heading of epilepsy, instead of only focusing on a particular kind of disorder brought on by a genetic mutation. Following are some of the domains transformed by gene therapy. Neurology – Gene therapy can be used for the treatment of seizures by directly injecting it into the area causing an uncontrolled electrical disturbance in the brain. Furthermore, by using DNA sequences known as promoters, gene therapy can be restricted to specific neurons within that area. Ophthalmology – Genetic conditions such as blindness can be caused due to the mutation of any gene out of over 200 and resulting in progressive vision loss in children. With advanced gene therapies such as optogenetics, lost photoreceptor function can be transferred to the retinal cells, which are responsible for relaying visual information to the brain. This might give patients the ability to navigate in an unknown environment with a certain level of autonomy. The Future of Gene Therapy The news surrounding gene therapy has been largely favorable over the past few years, with treatment after treatment obtaining regulatory approvals, successful clinical trials, and garnering significant funds to begin development. With more than 1,000 clinical trials presently underway, the long-awaited gene therapy revolution might finally be here.

Read More
MedTech

Expansion of BioPharma: Opportunities and Investments

Article | July 12, 2022

Biopharmaceutical innovations are among the most ingenious and refined achievements of modern medical science. New concepts, techniques, and therapies are emerging, such as the cell therapy Provenge, which can be used to treat cancer, and gene therapies, which provide even more amazing promises of disease remission and regenerative medicine. In addition, the COVID-19 pandemic has caused a huge boom in the pharmaceutical industry. This is because more and more attention is being paid to increasing manufacturing capacity and starting new research on drug development. Biopharma: Leading the Way in the Pharma Sector In the past couple of years, the biopharmaceutical sector has deepened its roots across the medical and pharmaceutical industries, on account of the transformation of pharmaceutical companies towards biotechnology, creating opportunities for growth. Also, growing advancements in technologies such as 3D bioprinting, biosensors, and gene editing, along with the integration of advanced artificial intelligence and virtual and augmented reality are estimated to further create prospects for growth. According to a study, the biopharmaceutical sector makes nearly $163 billion around the world and grows by more than 8% each year, which is twice as fast as the traditional pharma sector. Massive Investments Directed Towards Biopharma Investing in biotech research and development (R&D) has yielded better returns than the pharma industry average. Hence, a number of pharmaceutical companies are shifting their presence toward biopharma to capitalize on the upcoming opportunities by investing in and expanding their biotechnology infrastructure. For instance, Thermo Fisher Scientific Inc., an American manufacturer of scientific instrumentation, reagents and consumables, and software services, announced an investment of $97 million to expand its bioanalytical laboratory operations into three new locations in the U.S. With this investment, the company will add 150,000 square feet of scientific workspace and install the most advanced drug development technologies to produce life-changing medicines for patients in need.

Read More

Spotlight

StatRad

Built from the ground up by physicians for physicians, StatRad has been passionately dedicated to providing the very best in patient care while constantly improving our service to our partners through the latest advances in technology. Established in 1996, we partnered with local radiology groups to provide coverage after normal business hours. In 2001, we introduced an innovative teleradiology platform to accelerate transmissions, streamline workflows, increase productivity and improve communication among physicians. Today, we’re maintaining our pioneering spirit by introducing new innovations to the market on a regular basis and providing the technology, expertise and service to help our clients deliver excellent care.

Related News

The Power of Cannabis Hairs Revealed With Microscopy, Genetic Testing

LabRoots | November 01, 2019

A recent study from the University of British Columbia, published in The Plant Journal examined the hairs, or glandular trichomes, of cannabis plants. The structures and chemical outputs of various hairs were studied through microscopy and chemical profiling. The plant sample used was a quick-flowering variety of hemp Cannabis sativa known as “Finola.” The largest and mushroom-shaped “stalked” plant hairs were discovered to be the most potent; they produced the most THC- and CBD-forming metabolites and scent-producing terpenes. This fact has been previously suspected but unproven within the cannabis community. Earlier studies categorized the cannabis plant hairs as either bulbous, sessile or stalked, based on how they looked. But how they actually affected the strength of the plant’s effects was unknown. A gene expression analysis and UV light examinations helped the researchers to better understand the hairs’ properties. "We saw that stalked glandular trichomes have expanded ‘cellular factories’ to make more cannabinoids and fragrant terpenes. We also found that they grow from sessile-like precursors and undergo a dramatic shift during development that can be visualized using new microscopy tools,” co-lead author and Botany Ph.D. candidate Sam Livingston said.

Read More

Is There Really a Difference Between Indica and Sativa?

labroots | April 26, 2019

The idea that there are different strains, (Cannabis indica and Cannabis sativa), has almost become cannabis dogma. They look different, indicas are typically shorter and more scrub-like while sativas are taller. They came from different regions, indicas from Afghanistan and India and sativas from central America. They even are thought to have different effects. Indicas are thought to induce a sense of deep body relaxation, while sativas tend to produce an energizing experience. But is there any science to these claims? The idea that these strains are different species comes from the famous biologist Jean Baptiste Lamarck, known primarily being wrong about how species evolve. Lamark classified these strains as different species based primarily in the manner that we do today. According to an essay published by Jacob L. Erkelens and Arno Hazekamp in the journal Cannabinoids, Lamark distinguished the plant C. sativa, which was cultivated at the time, from a new variant of cannabis that grew wild in India, was thought to be a new species. In honor of the country that it came from, Lamarck called it C.indica (for India).

Read More

CanniMed Inks Canada’s First Pharmacy Cannabis Distribution Deal

biotech | March 02, 2017

This industry-leading collaboration will see CanniMed responsible for producing and delivering accredited pharmacy education programs to PharmaChoice pharmacists and pharmacy technicians across Canada. In addition, CanniMed and PharmaChoice intend to enter a definitive agreement for distribution of medical cannabis through PharmaChoice pharmacists in Canada upon completion of the first provincial legislation change that allows such distribution

Read More

The Power of Cannabis Hairs Revealed With Microscopy, Genetic Testing

LabRoots | November 01, 2019

A recent study from the University of British Columbia, published in The Plant Journal examined the hairs, or glandular trichomes, of cannabis plants. The structures and chemical outputs of various hairs were studied through microscopy and chemical profiling. The plant sample used was a quick-flowering variety of hemp Cannabis sativa known as “Finola.” The largest and mushroom-shaped “stalked” plant hairs were discovered to be the most potent; they produced the most THC- and CBD-forming metabolites and scent-producing terpenes. This fact has been previously suspected but unproven within the cannabis community. Earlier studies categorized the cannabis plant hairs as either bulbous, sessile or stalked, based on how they looked. But how they actually affected the strength of the plant’s effects was unknown. A gene expression analysis and UV light examinations helped the researchers to better understand the hairs’ properties. "We saw that stalked glandular trichomes have expanded ‘cellular factories’ to make more cannabinoids and fragrant terpenes. We also found that they grow from sessile-like precursors and undergo a dramatic shift during development that can be visualized using new microscopy tools,” co-lead author and Botany Ph.D. candidate Sam Livingston said.

Read More

Is There Really a Difference Between Indica and Sativa?

labroots | April 26, 2019

The idea that there are different strains, (Cannabis indica and Cannabis sativa), has almost become cannabis dogma. They look different, indicas are typically shorter and more scrub-like while sativas are taller. They came from different regions, indicas from Afghanistan and India and sativas from central America. They even are thought to have different effects. Indicas are thought to induce a sense of deep body relaxation, while sativas tend to produce an energizing experience. But is there any science to these claims? The idea that these strains are different species comes from the famous biologist Jean Baptiste Lamarck, known primarily being wrong about how species evolve. Lamark classified these strains as different species based primarily in the manner that we do today. According to an essay published by Jacob L. Erkelens and Arno Hazekamp in the journal Cannabinoids, Lamark distinguished the plant C. sativa, which was cultivated at the time, from a new variant of cannabis that grew wild in India, was thought to be a new species. In honor of the country that it came from, Lamarck called it C.indica (for India).

Read More

CanniMed Inks Canada’s First Pharmacy Cannabis Distribution Deal

biotech | March 02, 2017

This industry-leading collaboration will see CanniMed responsible for producing and delivering accredited pharmacy education programs to PharmaChoice pharmacists and pharmacy technicians across Canada. In addition, CanniMed and PharmaChoice intend to enter a definitive agreement for distribution of medical cannabis through PharmaChoice pharmacists in Canada upon completion of the first provincial legislation change that allows such distribution

Read More

Events